The US Molecular Diagnostics Market, Forecast to 2021

The US Molecular Diagnostics Market, Forecast to 2021

Polymerase Chain Reaction (PCR) Holds Close to 53% Share but Strong Clinical Research will Push NGS to Revolutionize this Space in the Next 5 to 10 Ye

RELEASE DATE
08-Nov-2016
REGION
North America
Research Code: K0AD-01-00-00-00
SKU: HC02688-NA-MR_19157

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC02688-NA-MR_19157

$4,950.00

$3,712.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher dominate in this field and are expected to maintain their positions in the market through mergers and acquisitions of smaller start-ups. Illumina maintains its monopoly in the NGS market followed by Thermo Fisher, which is likely to remain unchanged during the forecast years. The market continues to grow despite strict guidelines. Molecular diagnostics is expected to at least partially replace microbiology testing and other ELISA/ immunoassay based tests during the forecast years. This study discusses growth opportunities and trends and offers predictions for the 4 technology segments discussed above. Trends across therapeutic areas such as oncology, women's health, HIV/STDs, and infectious disease testing areas are also covered in this research. The study period is 2014 to 2021.

Key questions this study answers:

Will the molecular diagnostics market disrupt your current business or create growth opportunities? What do you need to know?
Where are the hottest segments in this market? Where is the most interest in terms of funding and innovation?
What are some of the most disruptive products by disease indication in this space?
What are the gaps in the market that encourage penetration and provide opportunities to new entrants?

Table of Contents

Scope and Segmentation

Executive Summary—Market Snapshot

  • Market Drivers
  • Points to Consider

Executive Summary—Key Questions Addressed in this Study

Key Factors Affecting this Market that Could Influence

Evolution of Molecular Diagnostics

Molecular Diagnostics Market More Complex Since Origins 20 Years Ago

  • Market Direction
  • M&A
  • Key Technologies
  • Emerging Technologies
  • Key Focus Areas

7 Big Market Directions in Molecular Diagnostics

Trends Driving Molecular Diagnostics in Healthcare

Key Predictions

  • Personalized Medicine
  • 4 Dominant Technologies
  • Moving Focus on Key Disease Areas
  • Regulatory Priority
  • IVD Leaders in Molecular Diagnostics
  • Opportunity in Companion Diagnostics
  • Emerging Technology
  • Molecular Diagnostics Expanding beyond Laboratory

Future of Molecular Diagnostics Market

Molecular Technologies in IVD—Growth Trends by Segment

  • Shift to value-based systems will spur growth in this market
  • Business focus is moving outside the US
  • NGS expanding into other diseases areas will increase competition
  • Molecular based POCTs are gaining momentum
  • Personalized medicine initiative drives companion diagnostics forward along with therapy monitoring

Key Companies to Watch

Molecular Diagnostics Growing Fastest within the IVD Industry

How is this Market Segmented?

Molecular Diagnostics Test Volume Estimation

Molecular Diagnostics Cross the Patient Care Continuum

  • US Molecular Diagnostics Market

Reimbursement of Molecular Tests

FDA versus LDT—Opportunity Expectations

Comparison of Molecular Diagnostic Techniques

Key Mergers, Acquisitions, and Partnerships

Largest Revenue Contributors to the Molecular Diagnostics Market by Disease

Platforms and Assay Availability by Top Manufacturers

Key Opportunities and Trends—Oncology Segment

Precision Medicine in Oncology

Rise of Computational Genomics

Value Proposition of MDx in Cancer to be Correlated with Reducing Price or Reimbursing Tests

Current Scenario in the Oncology Segment

Oncology Opportunities Through the Patient Continuum

US Competitive Landscape for Oncology Tests by Technology

Top Predictions for the Oncology Segment

Key Opportunities and Trends—Infectious Disease

The Culture of Culture Technology and ACA

HAI Diagnostics Penetrating Testing Sites

Infectious Disease Highest Growth Segment by Volume

Need-based Opportunities High in Infectious Diseases Especially in Niche Markets

Competitive Landscape for Infectious Disease Tests by Technology

Top Predictions for the Infectious Disease Segment

Key Opportunities and Trends—Women’s Health Segment

Opportunities in Cancer Screening, Prenatal Testing, and HPV

Breast Cancer—Opportunities Lie in Parallel Diagnosis and Screening Along with Imaging Technologies

Noninvasive Prenatal Testing (NIPT)—With Average Maternal Age Increasing, Opportunity Grows in the US

Prenatal Testing Brands Familiarity by End-user Type

Molecular Tests Becoming a Part of Routine Healthcare Visits for Women’s Health

Reimbursements—CPT Code List and Volume

Competitive Landscape for Women’s Health Tests by Technology

Top Predictions for the Women’s Health Segment

Key Opportunities and Trends—HIV Segment

HIV MDx Manufactures Focusing Away from the US, Seeking Opportunities Overseas

Reimbursement and Pricing Pressures Significantly Dropping Price of HIV Quant Tests

Immunodiagnostic Tests Have Similar HIV Tests for a Lower Cost and Simpler Workflow

Competitive Landscape HIV and STDs Tests by Technology

Top Predictions for the HIV/STDs Segment

Technology Overview

Growth Opportunities for Technology Providers

Market Projection for Overall Molecular Diagnostics

Overall Market Share by Vendor

Current Use of Technologies

Future Use of Technologies

PCR—An Array of Options

New Age of PCR—Multiplexing PCR Systems

FDA Approved Multiplex Tests on the Rise

PCR (Despite Being a Mature Technique) Growing as a Market Due to Technical Unmet Needs

Market Projection for PCR Market

Market Share Analysis for PCR

Selected Vendor Profiles—PCR

Top Predictions for the US PCR Market

5 Competitive Keys for Success in the PCR Space

Microarray Becoming a Flexible and Customizable Technology Important for Genomic Research

Market Projection for Microarray Market

Market Share Analysis for Microarray

Select Vendor Profiles—Microarray

Top Predictions for the US Microarray Market

5 Competitive Keys for Success in the Microarray Space

FISH Remains Progressive Field but Necessary to Confirm and Refine Results Before the Technology Can Come to Fruition

Market Projection for FISH Market

Market Share Analysis for FISH

Select Vendor Profiles—FISH

Top Predictions for the US FISH Market

5 Competitive Keys for Success in the FISH Space

NGS Systems Have High Capabilities but Still Need to Meet Fundamental Needs to Sustain Growth

Evidence of Cost per Raw Megabase and Cost per Genome Dropping Significantly Driving Market Adoption

Recent FDA Guideline to NGS in Infectious Disease to Offer Structure to a Rapidly Evolving Market

Market Projection for NGS Market

Market Share Analysis for NGS

Select Vendor Profiles—NGS

Top Predictions for the US NGS Market

5 Competitive Keys for Success in the NGS Space

A 4-step Guideline to Companion Diagnostics (CDx) Projects

What Has Changed in FDA Regulation of CDx in the Molecular Market?

Companion Diagnostics by Disease and Technology—PCR is Highly Prevalent in CDx

CNS, Infectious Diseases, and CV—The Next Big Opportunities for Molecular Diagnostics in CDx

Current and Future of Companion Diagnostics in MDx

Liquid Biopsy to Revolutionize the Therapeutic, Monitoring, and Drug Resistance Landscape for Genotyping

Liquid Biopsy to Become Mainstream within 1 to 4 Years in the United States

Technologies Used to Detect ctDNA

Technologies Used to Detect CTC

Large IVD Participants Expanding Product Portfolio to Include Liquid Biopsy

DTC Market Value Chain

DTC Offerings in the United States

Future Perspectives—3 Big Predictions

Key Conclusions and Future Outlook

List of Others

236 FDA Approved Assays and Systems

List of Figures
  • 1. Molecular Diagnostics Market: Platforms and Assay Availability by Top Manufacturers, US, 2015
  • 2. Molecular Diagnostics Market: Test Volume in Labs, US, 2015
  • 3. Molecular Diagnostics Market: Opportunities in Cancer Screening, Prenatal Testing, and HPV, US, 2015
  • 4. Molecular Diagnostics Market: Detection Rate, US, 2015
  • 5. Molecular Diagnostics Market: Company Market Share Analysis of Top 5 Participants, US, 2015
  • 6. Molecular Diagnostics Market: PCR Technology, US, 2015
  • 7. Total Molecular Diagnostics Market: DTC Offerings, US, 2015
List of Charts
  • 1. Molecular Diagnostics Market: Ecosystem, US, 2015
  • 2. Molecular Diagnostics Market: Market Trends, US, 2016, 2018, 2020
  • 3. Disease Segments: Market Direction, US, 2015
  • 4. Molecular Diagnostics Market: Market Growth/Potential, US, 2015
  • 5. IVD Industry: Segment Breakdown, Global, 2015
  • 6. Molecular Diagnostics Market: Market Segmentation, US, 2015
  • 7. Molecular Diagnostics Market: Test Volume Estimation, US, 2015
  • 8. Molecular Diagnostics Market: NG/CT/HPV Amplification Price per Test, US, 2010–2014
  • 9. Molecular Diagnostics Market: HIV Quant Price per Test, US, 2010–2014
  • 10. Molecular Diagnostics Market: Percent Revenue Breakdown by Disease segment, US, 2015–2021
  • 11. Molecular Diagnostics Market: Percent of Oncology Testing, US, 2015
  • 12. Molecular Diagnostics Market: Tests Count of Oncology, US, 2015
  • 13. Molecular Diagnostics Market: Market Share by Application, US, 2015
  • 14. Infectious Disease Segment: Test Volume MDx vs. Non-MDx Tests, Us, 2010–2015
  • 15. Genetic Disease Segment: Test Volume MDx vs. Non-MDx Tests, Us, 2010–2015
  • 16. Molecular Diagnostic Market: Tests Count of Infectious Diseases, US, 2015
  • 17. Molecular Diagnostics Market: Breast Cancer Opportunity, US, 2015
  • 18. Molecular Diagnostics Market: Prenatal Testing Brands Familiarity (Very Familiar Ratings), United States, 2015
  • 19. Molecular Diagnostics Market: Test Volume of Women’s Health, US, 2015
  • 20. Molecular Diagnostics Market: Prevalence Rate of HIV, US, 2010–2015E
  • 21. Molecular Diagnostics Market: Percent of People Living with HIV Worldwide, Global, 2015
  • 22. Molecular Diagnostics Market: HIV Quant PCR-based Test Prices, 2010–2015 (E)
  • 23. Molecular Diagnostics: FDA Approved Instruments and Assays by Technology, US, 2015
  • 24. Molecular Diagnostics Market: Revenue Forecast, US, 2014–2021
  • 25. Molecular Diagnostics Market: Percent Revenue Breakdown, US, 2015
  • 26. Molecular Diagnostics Market: Current Use of Technologies, US, 2015
  • 27. Molecular Diagnostics Market: Future Use of Technologies, US, 2015
  • 28. Molecular Diagnostics Market: Percent of Multiplexing Platforms/Assays Approved, US, 2015
  • 29. PCR Market: Revenue Forecast, US, 2014–2021
  • 30. PCR Market: Percent Revenue Breakdown, US, 2015
  • 31. Microarray Market: Revenue Forecast, US, 2014–2021
  • 32. Microarray Market: Percent Revenue Breakdown, US, 2015
  • 33. FISH Market: Revenue Forecast, US, 2014–2021
  • 34. FISH Market: Percent Revenue Breakdown, US, 2015
  • 35. Molecular Diagnostics Market: Cost Trend per Raw Megabase and Genome, US, 2010–2015
  • 36. NGS Market: Revenue Forecast, US, 2014–2021
  • 37. NGS Market: Percent Revenue Breakdown, US, 2015
  • 38. Molecular Diagnostics Market: CDx by Technology, US, 2015
  • 39. Molecular Diagnostics Market: Development of Companion Diagnostics in Other Disease Areas, US, 2015
  • 40. Molecular Diagnostics Market: Current and Future of Companion Diagnostics in MDx, US, 2015
  • 41. Molecular Diagnostics Market: Top Predicted Usage of Liquid Biopsy, US, 2015
  • 42. Molecular Diagnostics Market: Timeframe of Liquid Biopsy Replacing Solid Tumor Tissue Biopsy in the Future, US, 2015
  • 43. Molecular Diagnostics Market: Technologies Used to Detect ctDNA, US, 2015
  • 44. Molecular Diagnostics Market: Technologies Used to Detect CTCs, US, 2015
  • 45. Total Molecular Diagnostics Market: Key Conclusions and Future Outlook, US, 2015
Related Research
The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher dominate in this field and are expected to maintain their positions in the market through mergers and acquisitions of smaller start-ups. Illumina maintains its monopoly in the NGS market followed by Thermo Fisher, which is likely to remain unchanged during the forecast years. The market continues to grow despite strict guidelines. Molecular diagnostics is expected to at least partially replace microbiology testing and other ELISA/ immunoassay based tests during the forecast years. This study discusses growth opportunities and trends and offers predictions for the 4 technology segments discussed above. Trends across therapeutic areas such as oncology, women's health, HIV/STDs, and infectious disease testing areas are also covered in this research. The study period is 2014 to 2021. Key questions this study answers: Will the molecular diagnostics market disrupt your current business or create growth opportunities? What do you need to know? Where are the hottest segments in this market? Where is the most interest in terms of funding and innovation? What are some of the most disruptive products by disease indication in this space? What are the gaps in the market that encourage penetration and provide opportunities to new entrants?
More Information
No Index No
Podcast No
Table of Contents | Executive Summary to the Molecular Diagnostics Market~ || Scope and Segmentation~ || Executive Summary—Market Snapshot~ ||| Market Drivers~ ||| Points to Consider~ || Executive Summary—Key Questions Addressed in this Study~ | Market Overview~ || Key Factors Affecting this Market that Could Influence~ ||| Market Direction~ ||| M&A~ ||| Key Technologies~ ||| Emerging Technologies~ ||| Key Focus Areas~ || Evolution of Molecular Diagnostics~ || Molecular Diagnostics Market More Complex Since Origins 20 Years Ago~ || 7 Big Market Directions in Molecular Diagnostics~ ||| Personalized Medicine~ ||| 4 Dominant Technologies~ ||| Moving Focus on Key Disease Areas~ ||| Regulatory Priority~ ||| IVD Leaders in Molecular Diagnostics~ ||| Opportunity in Companion Diagnostics~ ||| Emerging Technology~ ||| Molecular Diagnostics Expanding beyond Laboratory~ || Trends Driving Molecular Diagnostics in Healthcare~ || Key Predictions~ ||| Shift to value-based systems will spur growth in this market~ ||| Business focus is moving outside the US~ ||| NGS expanding into other diseases areas will increase competition~ ||| Molecular based POCTs are gaining momentum~ ||| Personalized medicine initiative drives companion diagnostics forward along with therapy monitoring~ || Future of Molecular Diagnostics Market~ || Molecular Technologies in IVD—Growth Trends by Segment~ || Key Companies to Watch~ || Molecular Diagnostics Growing Fastest within the IVD Industry~ || How is this Market Segmented?~ ||| US Molecular Diagnostics Market~ |||| Disease Segments~ ||||| Oncology~ ||||| Infectious Diseases~ ||||| Women’s Health~ ||||| HIV/STDs~ |||| Technology Segments~ ||||| PCR~ ||||| FISH~ ||||| Microarray~ ||||| NGS~ || Molecular Diagnostics Test Volume Estimation~ || Molecular Diagnostics Cross the Patient Care Continuum~ || Reimbursement of Molecular Tests~ || FDA versus LDT—Opportunity Expectations~ | Competitive Landscape~ || Comparison of Molecular Diagnostic Techniques~ || Key Mergers, Acquisitions, and Partnerships~ | Disease Segments—Overview~ || Largest Revenue Contributors to the Molecular Diagnostics Market by Disease~ || Platforms and Assay Availability by Top Manufacturers~ | Oncology~ || Key Opportunities and Trends—Oncology Segment~ || Precision Medicine in Oncology~ || Rise of Computational Genomics~ || Value Proposition of MDx in Cancer to be Correlated with Reducing Price or Reimbursing Tests~ || Current Scenario in the Oncology Segment~ || Oncology Opportunities Through the Patient Continuum~ || US Competitive Landscape for Oncology Tests by Technology~ || Top Predictions for the Oncology Segment~ | Infectious Disease~ || Key Opportunities and Trends—Infectious Disease~ || The Culture of Culture Technology and ACA~ || HAI Diagnostics Penetrating Testing Sites~ || Infectious Disease Highest Growth Segment by Volume~ || Need-based Opportunities High in Infectious Diseases Especially in Niche Markets~ || Competitive Landscape for Infectious Disease Tests by Technology~ || Top Predictions for the Infectious Disease Segment~ | Women’s Health~ || Key Opportunities and Trends—Women’s Health Segment~ || Opportunities in Cancer Screening, Prenatal Testing, and HPV~ || Breast Cancer—Opportunities Lie in Parallel Diagnosis and Screening Along with Imaging Technologies~ || Noninvasive Prenatal Testing (NIPT)—With Average Maternal Age Increasing, Opportunity Grows in the US~ || Prenatal Testing Brands Familiarity by End-user Type~ || Molecular Tests Becoming a Part of Routine Healthcare Visits for Women’s Health~ || Reimbursements—CPT Code List and Volume~ || Competitive Landscape for Women’s Health Tests by Technology~ || Top Predictions for the Women’s Health Segment~ | HIV and STDs~ || Key Opportunities and Trends—HIV Segment~ || HIV MDx Manufactures Focusing Away from the US, Seeking Opportunities Overseas~ || Reimbursement and Pricing Pressures Significantly Dropping Price of HIV Quant Tests~ || Immunodiagnostic Tests Have Similar HIV Tests for a Lower Cost and Simpler Workflow~ || Competitive Landscape HIV and STDs Tests by Technology~ || Top Predictions for the HIV/STDs Segment~ | Technology Overview~ || Technology Overview~ || Growth Opportunities for Technology Providers~ || Market Projection for Overall Molecular Diagnostics~ || Overall Market Share by Vendor~ ||| Roche~ ||| Abbott~ ||| Cepheid~ ||| BD~ ||| Thermo Fisher~ ||| BioMeireux~ ||| Illumina~ ||| Others~ || Current Use of Technologies~ || Future Use of Technologies~ | Technology Segmentation—PCR~ || PCR—An Array of Options~ || New Age of PCR—Multiplexing PCR Systems~ || FDA Approved Multiplex Tests on the Rise~ || PCR (Despite Being a Mature Technique) Growing as a Market Due to Technical Unmet Needs~ || Market Projection for PCR Market~ || Market Share Analysis for PCR~ || Selected Vendor Profiles—PCR~ || Top Predictions for the US PCR Market~ || 5 Competitive Keys for Success in the PCR Space~ ||| Targeting Niche Areas~ ||| Platform Flexibility~ ||| FDA or LDT~ ||| Targeted Impact~ ||| Identifying Synergies for Partnership~ | Technology Segmentation—Microarray~ || Microarray Becoming a Flexible and Customizable Technology Important for Genomic Research~ || Market Projection for Microarray Market~ || Market Share Analysis for Microarray~ || Select Vendor Profiles—Microarray~ || Top Predictions for the US Microarray Market~ || 5 Competitive Keys for Success in the Microarray Space~ ||| Disease Areas~ ||| Population Analysis~ ||| Demand and Technology~ ||| Platform Flexibility~ ||| Combination Microarrays~ | Technology Segmentation—FISH~ || FISH Remains Progressive Field but Necessary to Confirm and Refine Results Before the Technology Can Come to Fruition~ || Market Projection for FISH Market~ || Market Share Analysis for FISH~ || Select Vendor Profiles—FISH~ || Top Predictions for the US FISH Market~ || 5 Competitive Keys for Success in the FISH Space~ ||| Disease Areas~ ||| Market Potential~ ||| Demand and Technology~ ||| Knowing Limitations~ ||| Reagent Cost~ | Technology Segmentation—NGS~ || NGS Systems Have High Capabilities but Still Need to Meet Fundamental Needs to Sustain Growth~ || Evidence of Cost per Raw Megabase and Cost per Genome Dropping Significantly Driving Market Adoption~ || Recent FDA Guideline to NGS in Infectious Disease to Offer Structure to a Rapidly Evolving Market~ || Market Projection for NGS Market~ || Market Share Analysis for NGS~ || Select Vendor Profiles—NGS~ || Top Predictions for the US NGS Market~ || 5 Competitive Keys for Success in the NGS Space~ ||| Disease Areas~ ||| Service Opportunity~ ||| Demand and Technology~ ||| Platform Flexibility~ ||| Regulation~ | Emerging Opportunities—Companion Diagnostics~ || A 4-step Guideline to Companion Diagnostics (CDx) Projects~ || What Has Changed in FDA Regulation of CDx in the Molecular Market?~ || Companion Diagnostics by Disease and Technology—PCR is Highly Prevalent in CDx~ || CNS, Infectious Diseases, and CV—The Next Big Opportunities for Molecular Diagnostics in CDx~ || Current and Future of Companion Diagnostics in MDx~ | Emerging Opportunities—Liquid Biopsy~ || Liquid Biopsy to Revolutionize the Therapeutic, Monitoring, and Drug Resistance Landscape for Genotyping~ || Liquid Biopsy to Become Mainstream within 1 to 4 Years in the United States~ || Technologies Used to Detect ctDNA~ || Technologies Used to Detect CTC~ || Large IVD Participants Expanding Product Portfolio to Include Liquid Biopsy~ | Emerging Opportunities—Direct-to-Consumer Testing~ || DTC Market Value Chain~ || DTC Offerings in the United States~ | Conclusion~ || Future Perspectives—3 Big Predictions~ || Key Conclusions and Future Outlook~ | Appendix~ || List of Others~ | 236 Systems and Assays~ || 236 FDA Approved Assays and Systems~ | The Frost & Sullivan Story~
List of Charts and Figures 1. Molecular Diagnostics Market: Platforms and Assay Availability by Top Manufacturers, US, 2015~ 2. Molecular Diagnostics Market: Test Volume in Labs, US, 2015~ 3. Molecular Diagnostics Market: Opportunities in Cancer Screening, Prenatal Testing, and HPV, US, 2015~ 4. Molecular Diagnostics Market: Detection Rate, US, 2015~ 5. Molecular Diagnostics Market: Company Market Share Analysis of Top 5 Participants, US, 2015~ 6. Molecular Diagnostics Market: PCR Technology, US, 2015~ 7. Total Molecular Diagnostics Market: DTC Offerings, US, 2015~| 1. Molecular Diagnostics Market: Ecosystem, US, 2015~ 2. Molecular Diagnostics Market: Market Trends, US, 2016, 2018, 2020~ 3. Disease Segments: Market Direction, US, 2015~ 4. Molecular Diagnostics Market: Market Growth/Potential, US, 2015~ 5. IVD Industry: Segment Breakdown, Global, 2015~ 6. Molecular Diagnostics Market: Market Segmentation, US, 2015~ 7. Molecular Diagnostics Market: Test Volume Estimation, US, 2015~ 8. Molecular Diagnostics Market: NG/CT/HPV Amplification Price per Test, US, 2010–2014~ 9. Molecular Diagnostics Market: HIV Quant Price per Test, US, 2010–2014~ 10. Molecular Diagnostics Market: Percent Revenue Breakdown by Disease segment, US, 2015–2021~ 11. Molecular Diagnostics Market: Percent of Oncology Testing, US, 2015~ 12. Molecular Diagnostics Market: Tests Count of Oncology, US, 2015~ 13. Molecular Diagnostics Market: Market Share by Application, US, 2015~ 14. Infectious Disease Segment: Test Volume MDx vs. Non-MDx Tests, Us, 2010–2015~ 15. Genetic Disease Segment: Test Volume MDx vs. Non-MDx Tests, Us, 2010–2015~ 16. Molecular Diagnostic Market: Tests Count of Infectious Diseases, US, 2015~ 17. Molecular Diagnostics Market: Breast Cancer Opportunity, US, 2015~ 18. Molecular Diagnostics Market: Prenatal Testing Brands Familiarity (Very Familiar Ratings), United States, 2015~ 19. Molecular Diagnostics Market: Test Volume of Women’s Health, US, 2015~ 20. Molecular Diagnostics Market: Prevalence Rate of HIV, US, 2010–2015E~ 21. Molecular Diagnostics Market: Percent of People Living with HIV Worldwide, Global, 2015~ 22. Molecular Diagnostics Market: HIV Quant PCR-based Test Prices, 2010–2015 (E)~ 23. Molecular Diagnostics: FDA Approved Instruments and Assays by Technology, US, 2015~ 24. Molecular Diagnostics Market: Revenue Forecast, US, 2014–2021~ 25. Molecular Diagnostics Market: Percent Revenue Breakdown, US, 2015~ 26. Molecular Diagnostics Market: Current Use of Technologies, US, 2015~ 27. Molecular Diagnostics Market: Future Use of Technologies, US, 2015~ 28. Molecular Diagnostics Market: Percent of Multiplexing Platforms/Assays Approved, US, 2015~ 29. PCR Market: Revenue Forecast, US, 2014–2021~ 30. PCR Market: Percent Revenue Breakdown, US, 2015~ 31. Microarray Market: Revenue Forecast, US, 2014–2021~ 32. Microarray Market: Percent Revenue Breakdown, US, 2015~ 33. FISH Market: Revenue Forecast, US, 2014–2021~ 34. FISH Market: Percent Revenue Breakdown, US, 2015~ 35. Molecular Diagnostics Market: Cost Trend per Raw Megabase and Genome, US, 2010–2015~ 36. NGS Market: Revenue Forecast, US, 2014–2021~ 37. NGS Market: Percent Revenue Breakdown, US, 2015~ 38. Molecular Diagnostics Market: CDx by Technology, US, 2015~ 39. Molecular Diagnostics Market: Development of Companion Diagnostics in Other Disease Areas, US, 2015~ 40. Molecular Diagnostics Market: Current and Future of Companion Diagnostics in MDx, US, 2015~ 41. Molecular Diagnostics Market: Top Predicted Usage of Liquid Biopsy, US, 2015~ 42. Molecular Diagnostics Market: Timeframe of Liquid Biopsy Replacing Solid Tumor Tissue Biopsy in the Future, US, 2015~ 43. Molecular Diagnostics Market: Technologies Used to Detect ctDNA, US, 2015~ 44. Molecular Diagnostics Market: Technologies Used to Detect CTCs, US, 2015~ 45. Total Molecular Diagnostics Market: Key Conclusions and Future Outlook, US, 2015~
Lightbox Content World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019
Author Aish Vivekanadan
Industries Healthcare
WIP Number K0AD-01-00-00-00
Is Prebook No